Aquestive Therapeutics, Inc.

NASDAQ:AQST

Drug Manufacturers - Specialty & Generic

Healthcare
$3.78 +5.08%

+$0.23 today

Market cap
$475.10M
Beta
1.45
P/E (TTM)
-8.3
EPS (TTM)
-$0.56
52W Low $2.93High $7.55

Volume 1.80M

Average 1.51M

AQST Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Aquestive Therapeutics, Inc.NASDAQ: AQST

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 76.0%

Gross margin was 76.0% in Q1 FY2026, up 17.9 pp from a year earlier. On a trailing-twelve-month basis it was 63.5%, down 4.9 pp year over year. Over 3 fiscal years it widened by 2.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
76.0%+20.8 pp QoQ
Last fiscal yearDec 2025
61.5%-7.5 pp YoY
LTMMar 2026
63.5%-4.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+17.9 pp——
1 year-7.5 pp——
3 years+2.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
61.5%
Year-over-year change
-7.5pp

Gross Margin vs competitors

How AQST compares with its peers on the latest reported figures

  • AQST's LTM Mar 2026 gross margin of 63.5% is the 7th highest of the 10 companies compared; the peer median is 82.9%.
  • Its year-over-year change of -4.9 pp is the lowest of 10, against a peer median of -1.0 pp.
  • Over three fiscal years its change of +2.1 pp compares with a peer median of +2.7 pp.
AQST Competitors Peer median
Gross Margin for AQST and competitors
Company Period LTM level YoY 3-year change
VNDAVanda Pharmaceuticals Inc.LTM Mar 202692.5% -1.0 pp+3.5 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202688.1% -0.5 pp+2.7 pp
ZVRAZevra Therapeutics, Inc.LTM Mar 202685.5% +6.7 pp-13.3 pp
CPIXCumberland Pharmaceuticals Inc.LTM Mar 202682.9% -1.4 pp+6.7 pp
ALKSAlkermes plcLTM Sep 202682.9% -3.2 pp+6.3 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 202681.6% +0.6 pp+2.2 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202660.7% +3.0 pp+14.2 pp
DERMJourney Medical CorporationLTM Mar 202660.4% -4.2 pp+1.1 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.3% -3.3 pp-0.4 pp
Peer median (excluding AQST) 82.9%-1.0 pp+2.7 pp

Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue50.83M47.68M50.58M57.56M44.55M
Cost of Revenue14.99M19.39M20.83M17.87M17.15M
Gross Profit35.84M28.29M29.75M39.69M27.39M
Gross Margin70.5%59.3%58.8%69.0%61.5%
Research & Development17.05M17.48M13.1M20.28M17.19M
Selling, General & Admin53.48M52.88M31.75M50.18M79.85M
Operating Expenses70.52M70.36M44.85M70.46M97.04M
Depreciation & Amortization2.96M2.39M1.35M718K559K
EBITDA(45.11M)(39.58M)1.18M(26.62M)(66.13M)
EBITDA Margin-88.8%-83.0%2.3%-46.2%-148.4%
Operating Income(34.68M)(42.07M)(15.1M)(30.77M)(69.65M)
Operating Margin-68.2%-88.2%-29.9%-53.5%-156.4%
Interest Income423K99K16.32M3.44M0
Interest Expense22.46M12.44M7.46M16.82M17.1M
Other Income / Expenses(35.86M)(12.34M)7.48M(13.38M)(14.13M)
Income Before Tax(70.54M)(54.41M)(7.63M)(44.15M)(83.78M)
Pre-Tax Margin-138.8%-114.1%-15.1%-76.7%-188.1%
Income Tax Expense00245K(14K)0
Net Income(70.54M)(54.41M)(7.87M)(44.14M)(83.78M)
Net Margin-138.8%-114.1%-15.6%-76.7%-188.1%
EPS (Basic)(1.85)(1.12)(0.13)(0.51)(0.76)
EPS (Diluted)(1.85)(1.12)(0.13)(0.51)(0.76)
Weighted Avg Shares38.08M48.73M61.26M86.73M121.97M
Weighted Avg Shares (Diluted)38.08M48.73M61.26M86.73M121.97M

Aquestive Therapeutics, Inc.

NASDAQ:AQST

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.